Biopharmaceutical Research Unit, Novo Nordisk A/S, Maaloev, Denmark.
Haemophilia. 2010 Mar;16(2):349-59. doi: 10.1111/j.1365-2516.2009.02135.x. Epub 2009 Nov 11.
A new recombinant factor VIII (FVIII), N8, has been produced in Chinese hamster ovary (CHO) cells. The molecule consists of a heavy chain of 88 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa. The two chains are held together by non-covalent interactions. The four-step purification includes capture, affinity purification using a monoclonal recombinant antibody, anion exchange chromatography and gel filtration. The specific clotting activity of N8 was 8800-9800 IU mg(-1). Sequence and mass spectrometry analysis revealed two variants of the light chain, corresponding to two alternative N-terminal sequences also known from plasma FVIII. Two variants of the heavy chain are present in the purified product, namely with and without the B-domain linker attached. This linker is removed upon thrombin activation of N8 rendering an activated FVIII (FVIIIa) molecule similar to plasma FVIIIa. All six known tyrosine sulphations of FVIII were confirmed in N8. Two N-linked glycosylations are present in the A3 and C1 domain of the light chain and two in the A1 domain of the heavy chain. The majority of the N-linked glycans are sialylated bi-antennary structures. An O-glycosylation site is present in the B-domain linker region. This site was glycosylated with a doubly sialylated GalNAc-Gal structure in approximately 65% of the product. In conclusion, the present data show that N8 is a pure and well-characterized FVIII product with biochemical properties that equal other FVIII products.
一种新型的重组凝血因子 VIII(FVIII)N8 已在中国仓鼠卵巢(CHO)细胞中生产。该分子由一条 88 kDa 的重链组成,其中包含 21 个氨基酸残基的截断 B 结构域和一条 79 kDa 的轻链。两条链通过非共价相互作用结合在一起。四步纯化包括捕获、使用单克隆重组抗体的亲和纯化、阴离子交换色谱和凝胶过滤。N8 的特定凝血活性为 8800-9800IUmg(-1)。序列和质谱分析揭示了轻链的两种变体,对应于两种已知的血浆 FVIII 的替代 N 末端序列。在纯化产物中存在两种变体的重链,即带有和不带有 B 结构域接头。该接头在 N8 的凝血酶激活时被去除,生成类似于血浆 FVIIIa 的激活型 FVIII(FVIIIa)分子。所有六种已知的 FVIII 酪氨酸硫酸化在 N8 中均得到确认。N8 中存在两条轻链 A3 和 C1 结构域中的 N-连接糖基化和两条重链 A1 结构域中的 N-连接糖基化。大多数 N-连接糖基化是唾液酸化的双触角结构。在 B 结构域接头区域存在一个 O-连接糖基化位点。该位点在约 65%的产物中与双唾液酸化的 GalNAc-Gal 结构糖基化。总之,目前的数据表明,N8 是一种纯的、特征良好的 FVIII 产物,具有与其他 FVIII 产物相当的生化特性。